专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090136570A1 Taste-Masked Tablets and Granules 审中-公开
标题翻译：味道掩蔽的片剂和颗粒
公开(公告)号：US20090136570A1
公开(公告)日：2009-05-28
申请号：US12087827
申请日：2007-01-16
申请人： Bhagwant Rege , Kimberly Kaighn , Soumojeet Ghosh , Laman Alani
发明人： Bhagwant Rege , Kimberly Kaighn , Soumojeet Ghosh , Laman Alani
IPC分类号： A61K9/20 , A61K31/513 , A61K31/519 , A61P31/18 , A61K31/506
CPC分类号： A61K9/2054 , A61K9/2018 , A61K9/2027 , A61K9/2095 , A61K31/70
摘要： Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS.
摘要翻译：口服给药的掩味片和颗粒剂含有（a）羟基嘧啶酮羧酰胺，羟基四氢吡啶并嘧啶酮羧酰胺或相关的羧酰胺化合物或其药学上可接受的盐，（b）掩味聚合物，（c）超级崩解剂，和任选的其它赋形剂。甲酰胺化合物是HIV整合酶抑制剂，片剂和颗粒剂适用于抑制HIV整合酶，治疗或预防HIV感染，以及治疗或预防或延迟艾滋病的发作。

2. 发明授权

US08486983B2 Self-emulsifying formulations of CETP inhibitors 有权
标题翻译： CETP抑制剂的自乳化制剂
公开(公告)号：US08486983B2
公开(公告)日：2013-07-16
申请号：US12085745
申请日：2006-12-05
申请人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. McKelvey
发明人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. McKelvey
IPC分类号： A61K31/421
CPC分类号： A61K9/08 , A61K9/4858 , A61K31/421 , A61K47/10 , A61K47/26 , A61K47/44
摘要： A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
摘要翻译：用于口服给予式（I）的CETP抑制剂的液体制剂与常规固体制剂相比具有改善的生物利用度。该制剂包含CETP抑制剂或其药学上可接受的盐; 一油和一种或多种亲水亲油平衡（HLB）> 10的非离子表面活性剂。

3. 发明授权

US08414921B2 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin 有权
标题翻译：二肽基肽酶-4抑制剂与二甲双胍的组合药物组合物
公开(公告)号：US08414921B2
公开(公告)日：2013-04-09
申请号：US12085722
申请日：2006-12-12
申请人： Ashkan Kamali , Laman Alani , Kyle A. Fliszar , Soumojeet Ghosh , Monica Tijerina
发明人： Ashkan Kamali , Laman Alani , Kyle A. Fliszar , Soumojeet Ghosh , Monica Tijerina
IPC分类号： A61K9/20
CPC分类号： A61K9/2077 , A61K9/1635 , A61K9/2813 , A61K9/284 , A61K31/155 , A61K31/4985 , A61K38/04 , A61K45/06 , A61K2300/00
摘要： Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
摘要翻译：公开了包含二肽基肽酶-4抑制剂和二甲双胍的固定剂量组合的药物组合物，制备这种药物组合物的方法，以及用这种药物组合物治疗2型糖尿病的方法。

4. 发明授权

US07981911B2 Pharmaceutical formulations 有权
标题翻译：药物制剂
公开(公告)号：US07981911B2
公开(公告)日：2011-07-19
申请号：US12183507
申请日：2008-07-31
申请人： Laman Alani , Soumojeet Ghosh
发明人： Laman Alani , Soumojeet Ghosh
IPC分类号： A61K31/25
CPC分类号： A61K31/425
摘要： Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
摘要翻译：提供改进的药物组合物，其包含一种或多种在培养基和/或长链脂肪酸或其混合物，药学上可接受的醇和水中具有改善的溶解性质的增溶的HIV蛋白酶抑制化合物。

5. 发明申请

US20080181948A1 SOLID PHARMACEUTICAL DOSAGE FORMULATIONS 审中-公开
标题翻译：固体药物制剂
公开(公告)号：US20080181948A1
公开(公告)日：2008-07-31
申请号：US11939640
申请日：2007-11-14
申请人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Katja Fastnacht , Tina Jung , Wolfgang Roth , Joerg Breitenbach , John Morris , Cheri E. Klein , Yan Cai , Laman Alani , Soumojeet Ghosh
发明人： Gunther Berndl , Joerg Rosenberg , Bernd Liepold , Katja Fastnacht , Tina Jung , Wolfgang Roth , Joerg Breitenbach , John Morris , Cheri E. Klein , Yan Cai , Laman Alani , Soumojeet Ghosh
IPC分类号： A61K9/28 , A61K31/427 , A61P31/18 , A61K9/107
CPC分类号： A61K31/427 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2095
摘要： The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.
摘要翻译：本发明的特征在于包含利托那韦的固体药物剂型。作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。

6. 发明授权

US08501219B2 Flavoring systems for pharmaceutical compositions and methods of making such compositions 有权
公开(公告)号：US08501219B2
公开(公告)日：2013-08-06
申请号：US12687479
申请日：2010-01-14
申请人： Laman Alani , Donald P. Gauwitz , Dilip Kaul , John M. Lipari , Soumojeet Ghosh , Kennan C. Marsh , Richard H. Whelan , Vanik D. Petrossian
发明人： Laman Alani , Donald P. Gauwitz , Dilip Kaul , John M. Lipari , Soumojeet Ghosh , Kennan C. Marsh , Richard H. Whelan , Vanik D. Petrossian
IPC分类号： A61K47/00 , A61K9/00
CPC分类号： A61K47/46 , A61K9/0095 , A61K47/02 , A61K47/12
摘要： A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.

7. 发明申请

US20100280055A1 Flavoring Systems for Pharmaceutical Compositions and Methods of Making Such Compositions 有权
标题翻译：药物组合物调味剂系统及其制备方法
公开(公告)号：US20100280055A1
公开(公告)日：2010-11-04
申请号：US12687479
申请日：2010-01-14
申请人： Laman Alani , Donald P. Gauwitz , Dilip Kaul , John M. Lipari , Soumojeet Ghosh , Kennan C. Marsh , Richard H. Whelan , Vanik D. Petrossian
发明人： Laman Alani , Donald P. Gauwitz , Dilip Kaul , John M. Lipari , Soumojeet Ghosh , Kennan C. Marsh , Richard H. Whelan , Vanik D. Petrossian
IPC分类号： A61K31/513 , A61K31/427 , A61P31/18
CPC分类号： A61K47/46 , A61K9/0095 , A61K47/02 , A61K47/12
摘要： A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.
摘要翻译：公开了一种用于液体药物组合物的调味体系和含有这种调味体系的药物组合物。本发明的调味系统包括至少一种甜味剂，至少两种调味成分和至少一种选自柠檬酸，柠檬酸钠，氯化钠及其混合物的调味剂。至少两种调味成分选自香草调味成分，薄荷调味成分，薄荷醇风味成分，棉花糖调味成分及其混合物。一种或多种甜味剂包括甘油，甘草酸单铵盐，糖精钠，乙酰磺胺酸钾，高果糖玉米糖浆和/或其混合物。本发明的药物组合物包括本发明的调味剂体系，溶剂体系和至少一种药物活性剂，例如洛匹那韦或其衍生物，利托那韦或其衍生物，或其混合物。还公开了制备这种液体药物组合物的方法。

8. 发明申请

US20050191324A1 Flavoring systems for pharmaceutical compositions and methods of making such compositions 审中-公开
标题翻译：用于药物组合物的调味剂系统和制备这种组合物的方法
公开(公告)号：US20050191324A1
公开(公告)日：2005-09-01
申请号：US11118733
申请日：2005-04-29
申请人： Laman Alani , Donald Gauwitz , Dilip Kaul , John Lipari , Soumojeet Ghosh , Kennan Marsh , Richard Whelan , Vanik Petrossian
发明人： Laman Alani , Donald Gauwitz , Dilip Kaul , John Lipari , Soumojeet Ghosh , Kennan Marsh , Richard Whelan , Vanik Petrossian
IPC分类号： A61K9/00 , A61K31/7056
CPC分类号： A61K47/46 , A61K9/0095 , A61K47/02 , A61K47/12
摘要： A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.
摘要翻译：公开了一种用于液体药物组合物的调味体系和含有这种调味体系的药物组合物。本发明的调味系统包括至少一种甜味剂，至少两种调味成分和至少一种选自柠檬酸，柠檬酸钠，氯化钠及其混合物的调味剂。至少两种调味成分选自香草调味成分，薄荷调味成分，薄荷醇风味成分，棉花糖调味成分及其混合物。一种或多种甜味剂包括甘油，甘草酸单铵盐，糖精钠，乙酰磺胺酸钾，高果糖玉米糖浆和/或其混合物。本发明的药物组合物包括本发明的调味剂体系，溶剂体系和至少一种药物活性剂，例如洛匹那韦或其衍生物，利托那韦或其衍生物，或其混合物。还公开了制备这种液体药物组合物的方法。

9. 发明申请

US20090123538A1 Angiotensin II Receptor Antagonists 审中-公开
标题翻译：血管紧张素II受体拮抗剂
公开(公告)号：US20090123538A1
公开(公告)日：2009-05-14
申请号：US11886553
申请日：2006-04-14
申请人： Laman L. Alani , David C. Dubost , Bruce S. Foster , Soumojeet Ghosh , Hossain Jahansouz , Nazaneen Pourkavoos , Bhagwant Rege , Aditya Tatavarti
发明人： Laman L. Alani , David C. Dubost , Bruce S. Foster , Soumojeet Ghosh , Hossain Jahansouz , Nazaneen Pourkavoos , Bhagwant Rege , Aditya Tatavarti
IPC分类号： A61K9/20 , C07D257/04 , A61K31/41 , A61P9/12 , A61K9/16
CPC分类号： C07D403/10
摘要： The compounds of the present invention are polymorphic crystalline forms of the compound 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid, which has the structure (I). Specifically, the compounds of the invention are selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid of Claim 3 selected from the group consisting of 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form I, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form II, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid hydrochloride Form III, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form IV, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form V, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VI, 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VII, and 2-butyl-4-chloro-1-[(2′-(1-H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate Form VIII.
摘要翻译：本发明的化合物是2-丁基-4-氯-1 - （（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-1-基的化合物的多晶型形式，其具有结构（I）。具体地说，本发明化合物选自2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑 -5-羧酸，其选自2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑 -5-甲酸盐酸盐形式I，2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸盐酸盐形式II，2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸盐酸盐形式III和 2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式IV，2-丁基-4 - 氯 - 1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式V，2-丁基-4-氯-1- 甲基] - 咪唑-5-羧酸一水合物形式VI，2-丁基-4-氯-1 - [（2' - （1H-四唑-5-基）联苯-4-基）（1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5- c 羧酸一水合物形式VII和2-丁基-4-氯-1 - [（2' - （1-H-四唑-5-基）联苯-4-基）甲基] - 咪唑-5-甲酸一水合物形式八，

10. 发明申请

US20090186926A1 Self-Emulsifying Formulations of CETP Inhibitors 有权
标题翻译： CETP抑制剂的自乳化制剂
公开(公告)号：US20090186926A1
公开(公告)日：2009-07-23
申请号：US12085745
申请日：2006-12-05
申请人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. Mckelvey
发明人： Agam R. Sheth , Bhagwant Rege , Soumojeet Ghosh , Laman L. Alani , Maria T. Cruanes , Craig A. Mckelvey
IPC分类号： A61K31/421
CPC分类号： A61K9/08 , A61K9/4858 , A61K31/421 , A61K47/10 , A61K47/26 , A61K47/44
摘要： A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
摘要翻译：用于口服给予式（I）的CETP抑制剂的液体制剂与常规固体制剂相比具有改善的生物利用度。该制剂包含CETP抑制剂或其药学上可接受的盐; 一油和一种或多种亲水亲油平衡（HLB）> 10的非离子表面活性剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式